Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Profound Medical (PROF) Non-Current Deffered Revenue (2023 - 2025)

Historic Non-Current Deffered Revenue for Profound Medical (PROF) over the last 3 years, with Q3 2025 value amounting to $148000.0.

  • Profound Medical's Non-Current Deffered Revenue changed N/A to $148000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $148000.0, marking a year-over-year change of. This contributed to the annual value of $49000.0 for FY2024, which is 9326.92% down from last year.
  • Per Profound Medical's latest filing, its Non-Current Deffered Revenue stood at $148000.0 for Q3 2025.
  • Profound Medical's Non-Current Deffered Revenue's 5-year high stood at $728000.0 during Q4 2023, with a 5-year trough of $49000.0 in Q4 2024.
  • Over the past 3 years, Profound Medical's median Non-Current Deffered Revenue value was $85000.0 (recorded in 2025), while the average stood at $216800.0.
  • Over the last 5 years, Profound Medical's Non-Current Deffered Revenue had its largest YoY gain of 9326.92% in 2024, and its largest YoY loss of 9326.92% in 2024.
  • Quarter analysis of 3 years shows Profound Medical's Non-Current Deffered Revenue stood at $728000.0 in 2023, then tumbled by 93.27% to $49000.0 in 2024, then skyrocketed by 202.04% to $148000.0 in 2025.
  • Its Non-Current Deffered Revenue was $148000.0 in Q3 2025, compared to $74000.0 in Q2 2025 and $85000.0 in Q1 2025.